美国疾控中心:民众疫苗接种率已较高,不再建议保持社交距离、密接者免隔离,转向保护重症患者为主

2022-08-13 中国新闻网 中国新闻网

美国疾病控制和预防中心(CDC)当地时间11日更新了针对新冠疫情的防疫指引,取消保持“社交距离”等内容。

美国疾病控制和预防中心(CDC)当地时间11日更新了针对新冠疫情的防疫指引,取消保持“社交距离”等内容。

在当天发布的更新版防疫指引中,CDC取消了自疫情暴发初期开始实施的保持6英尺(约2米)“社交距离”的要求;对于密切接触者的追踪将仅限于医院、养老院等高风险群体;不再强调定期检测;新冠密切接触但未感染者无需再进行隔离。

CDC保留的防疫内容包括建议有类似感冒症状者以及密切接触者进行新冠检测;新冠检测结果呈阳性者需居家隔离至少5天,之后10天外出需佩戴口罩等。

This figure is a graphic describing guidance to help you make informed decisions to prevent severe <a href='https://www.medsci.cn/search?q=COVID-19'>COVID-19</a>. This includes four steps: know your risk, protect yourself, take action if exposed, and take action if you are sick or test positive.

CDC专家马塞蒂(Greta Massetti)表示,更新防疫指引的原因是当前的疫情状况已经与过去两年有很大不同。“很高比例的群体已经通过疫苗或者感染获得了免疫,当前的重心可以放在保护重症患者上面。”

更新指南的主要原因被认为,随着疫苗和感染引起的高水平免疫以及有效治疗和预防工具的可用性大大降低了具有医学意义的 COVID-19 的风险疾病(严重急性疾病和 COVID-19 后遗症)以及相关的住院和死亡。上述这些情况现在允许公共卫生努力通过关注可持续措施来进一步减少医学上的重大疾病以及尽量减少对医疗保健系统的压力,同时减少社会、教育、和经济活动。

具有医学意义的 COVID-19 的个体风险取决于一个人暴露于 SARS-CoV-2 的风险以及他们在感染后发展为严重疾病的风险。可以通过非药物干预措施降低暴露风险,包括改善通风、在室内使用口罩或呼吸器以及测试。医学上重大疾病的风险随着年龄、残疾状况和潜在的医疗状况而增加,但通过疫苗接种、既往感染或两者兼而有之的免疫力,以及及时获得有效的生物医学预防措施和治疗,风险会大大降低 。

CDC 的公共卫生建议会随着科学、生物医学和公共卫生工具的可及性不断发展以及环境变化(例如人群的免疫水平和当前流行的变异)而变化。 CDC 建议采取的策略,以尽量减少 COVID-19 对健康和社会的影响,该方法:

  • 依靠疫苗接种和治疗来预防重症的发生;
  • 在可行的情况下使用多种措施预防;
  • 特别强调保护重病高危人群。

应加强努力扩大疫苗接种和治疗的可及性,包括对免疫功能低下的人使用暴露前预防、抗病毒药物和治疗性单克隆抗体,以降低医学上重大疾病和死亡的风险。保护重病高危人群的努力必须确保所有人都能获得信息以了解他们的个人风险,以及有效和公平地获得疫苗接种、治疗、检测和其他预防措施。

当前预防医学上重大疾病的优先事项应侧重于确保人们 :

1)了解他们的风险,

2)在需要时采取措施通过疫苗、治疗和非药物干预措施保护自己和他人,

3)接受检测并戴上口罩

4)如果他们已经有症状,建议接受检测,如果他们被感染,则隔离 ≥5 天。

尽管CDC更新防疫指引,但美国新增新冠病例数仍然保持在“高位”。CDC数据显示,10日新增13万例新冠病例,近7日日均新增病例数超过10万例,远高于4月初日均2.5万例的数字;死亡人数方面,10日新增666例死亡病例,近7日日均死亡病例数为400例。

华盛顿大学一项研究称,由于当前众多民众选择在家自测不上报结果,因此实际感染新冠人数可能比统计数据高出7倍。

据美国约翰斯·霍普金斯大学最新统计数据显示,截至11日22时,美国累计新冠确诊病例超过9271万例,死亡病例超过103.6万例。

参考资料:

https://www.cdc.gov/mmwr/volumes/71/wr/mm7133e1.htm?s_cid=mm7133e1_w

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078686, encodeId=163f20e868693, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Jul 14 17:54:06 CST 2023, time=2023-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258176, encodeId=841812581e6a0, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284140, encodeId=82d71284140c6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405379, encodeId=10e114053e9fa, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570106, encodeId=b9bc15e010688, content=<a href='/topic/show?id=9dfae393265' target=_blank style='color:#2F92EE;'>#社交距离#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73932, encryptionId=9dfae393265, topicName=社交距离)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66c915628131, createdName=jiadan198787, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603484, encodeId=1a0216034842b, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=)]
    2023-07-14 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078686, encodeId=163f20e868693, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Jul 14 17:54:06 CST 2023, time=2023-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258176, encodeId=841812581e6a0, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284140, encodeId=82d71284140c6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405379, encodeId=10e114053e9fa, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570106, encodeId=b9bc15e010688, content=<a href='/topic/show?id=9dfae393265' target=_blank style='color:#2F92EE;'>#社交距离#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73932, encryptionId=9dfae393265, topicName=社交距离)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66c915628131, createdName=jiadan198787, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603484, encodeId=1a0216034842b, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078686, encodeId=163f20e868693, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Jul 14 17:54:06 CST 2023, time=2023-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258176, encodeId=841812581e6a0, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284140, encodeId=82d71284140c6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405379, encodeId=10e114053e9fa, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570106, encodeId=b9bc15e010688, content=<a href='/topic/show?id=9dfae393265' target=_blank style='color:#2F92EE;'>#社交距离#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73932, encryptionId=9dfae393265, topicName=社交距离)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66c915628131, createdName=jiadan198787, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603484, encodeId=1a0216034842b, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078686, encodeId=163f20e868693, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Jul 14 17:54:06 CST 2023, time=2023-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258176, encodeId=841812581e6a0, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284140, encodeId=82d71284140c6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405379, encodeId=10e114053e9fa, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570106, encodeId=b9bc15e010688, content=<a href='/topic/show?id=9dfae393265' target=_blank style='color:#2F92EE;'>#社交距离#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73932, encryptionId=9dfae393265, topicName=社交距离)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66c915628131, createdName=jiadan198787, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603484, encodeId=1a0216034842b, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=)]
    2022-08-14 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078686, encodeId=163f20e868693, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Jul 14 17:54:06 CST 2023, time=2023-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258176, encodeId=841812581e6a0, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284140, encodeId=82d71284140c6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405379, encodeId=10e114053e9fa, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570106, encodeId=b9bc15e010688, content=<a href='/topic/show?id=9dfae393265' target=_blank style='color:#2F92EE;'>#社交距离#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73932, encryptionId=9dfae393265, topicName=社交距离)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66c915628131, createdName=jiadan198787, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603484, encodeId=1a0216034842b, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2078686, encodeId=163f20e868693, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Jul 14 17:54:06 CST 2023, time=2023-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258176, encodeId=841812581e6a0, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284140, encodeId=82d71284140c6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405379, encodeId=10e114053e9fa, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570106, encodeId=b9bc15e010688, content=<a href='/topic/show?id=9dfae393265' target=_blank style='color:#2F92EE;'>#社交距离#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73932, encryptionId=9dfae393265, topicName=社交距离)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66c915628131, createdName=jiadan198787, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603484, encodeId=1a0216034842b, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Aug 14 23:54:06 CST 2022, time=2022-08-14, status=1, ipAttribution=)]
    2022-08-14 fengyi818

相关资讯

上海昨日新增本土5+42,均在隔离管控中发现:上海疫情最新消息(2022.7.14)

均为本市闭环隔离管控人员,其间新冠病毒核酸检测结果异常。

国家卫健委:昨日新增本土64+368,现有确诊中仅1重症病例(2022.7.15)

7月14日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例113例。其中境外输入病例49例(福建13例,广东11例,上海5例,内蒙古3例,重庆3例,四川3例,云南3

国家卫生健康委:昨日新增本土86+206:全国疫情最新消息(2022.7.14)

31个省(自治区、直辖市)和新疆生产建设兵团报告,现有确诊病例1119例(无重症病例)。

国家卫健委:31省区市7月16日新增本土病例“106+474”例(2022.7.17)

7月16日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例154例。其中境外输入病例48例(福建10例,广东10例,上海6例,天津4例,重庆3例,四川3例,北京2例

国家卫生健康委:昨日新增本土337+399:全国疫情最新消息(2022.8.7)

31个省(自治区、直辖市)和新疆生产建设兵团现有确诊病例2009例(其中重症病例2例)。